Absence of palivizumab escapes mutant for the Respiratory Syncytial Virus (RSV) circuling, in the city of São Paulo during the year of 2004.

Author(s)

Patrícia Alves Ramos Bosso

• Document type: Doctoral Thesis
• Press: São Paulo.
• Institution: Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI)
• Defense date: 2008-12-15

Examining board members

Edison Luiz Durigon; João Manuel Grisi Candeias; Antônio José Piantino Ferreira; José Antonio Jerez; César Augusto Dinóla Pereira

• Advisor: Edison Luiz Durigon

Abstract

The Respiratory Syncytial Virus (RSV) is the most common cause of lower respiratory tract disease in infants and young children. RSV has high rates of hospital admission and the frequency and severity of infections caused by RSV were assessed in children 2 years of age. In our study the frequency of RSV detection during 2004 was 43% (188/435) of the samples collected from Hospital University/USP in São Paulo city. Partial sequences of G protein gene of 45 isolates from group antigenic A and 8 isolates from antigenic group B were clustered into previously characterized genotypes: GA2,GA5,SAB1, SAB4 e BA like, respectively. Palivizumab (PZ) is the only monoclonal antibody currently available for uses in humans against RSV infectious disease. Here we evaluated the potential for PZ-resistant RSV mutants to arise in clinical samples. Samples from aspirates nasopharyngeal, reverse-PCR-amplified F gene fragments, and the nucleotide sequences were determined. In thirty sequences no revealed F gene mutations. This work shows that palivizumab prophylaxis is safe and efficacious. (AU)